Skip to main navigation

AnaptysBio

Investor Relations

  • About
    • Overview
    • Strategy
    • Management
    • Board of Directors
    • Research and Development Committee
    • Contact
  • Technology
    • Therapeutic Antibodies
    • Somatic Hypermutation
    • SHM Platform
    • Key Advantages
    • Publications
  • Pipeline
    • Overview
    • Imsidolimab
    • ANB030
    • ANB032
    • Partnerships
  • Investors / News
    • Overview
    • News
    • Events
    • Presentations
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact
  • Careers
    • Job Openings
    • Health and Financial Benefits Overview
  • Contact
Toggle

Events

Events

AnaptysBio, Inc. at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 13, 2021 at 7:00 AM EDT
Click here for webcast

Tools

  • Print

    Print
  • Email

    Email
  • RSS Feeds

    RSS Feeds
  • Email Alerts

    Email Alerts
  • Investor Contact

    Investor Contact
  • Document Request

    Document Request
 
  • About
    • Overview
    • Strategy
    • Management
    • Board of Directors
    • Therapeutic Advisory Board
  • Technology
    • Therapeutic Antibodies
    • Somatic Hypermutation
    • SHM Platform
    • Key Advantages
    • Publications
  • Pipeline
    • Overview
    • Etokimab
    • ANB019
    • Partnerships
  • Investors
    • Overview
    • News
    • Events
    • Goverance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • FAQs
    • Contact
  • Careers
    • Job Openings
    • Health and Financial Benefits Overview
  • Contact
Connect LinkedIn Twitter
©2018 AnaptysBio, Inc. All Rights Reserved. Terms Of Use